Multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany (Lp(a)FRONTIERS APHERESIS, NCT05305664)

Please login or create a FREE account to view this content